Following transscleral tumor therapy and EGFR-TKI therapy, the patient achieved a best corrected visual acuity (BCVA) of 20/20 in both eyes with controlled tumor progression, surviving with stable disease for 3 years. Here, EGFR is linked to neoplasm.